PL387051A1 - Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynie - Google Patents
Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynieInfo
- Publication number
- PL387051A1 PL387051A1 PL38705109A PL38705109A PL387051A1 PL 387051 A1 PL387051 A1 PL 387051A1 PL 38705109 A PL38705109 A PL 38705109A PL 38705109 A PL38705109 A PL 38705109A PL 387051 A1 PL387051 A1 PL 387051A1
- Authority
- PL
- Poland
- Prior art keywords
- dihydrophtalazine
- medicine
- amino
- manufacturing
- application
- Prior art date
Links
- 229910052783 alkali metal Inorganic materials 0.000 title 1
- 150000001340 alkali metals Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL387051A PL231885B1 (pl) | 2009-01-16 | 2009-01-16 | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| US13/144,838 US8536171B2 (en) | 2009-01-16 | 2010-01-15 | Method for obtaining 5-amino 2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
| EP10705930.5A EP2389364B1 (en) | 2009-01-16 | 2010-01-15 | New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
| EP16165549.3A EP3072888A1 (en) | 2009-01-16 | 2010-01-15 | Use of 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts in medicine |
| PCT/PL2010/000005 WO2010082858A2 (en) | 2009-01-16 | 2010-01-15 | New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
| US14/027,901 US9101629B2 (en) | 2009-01-16 | 2013-09-16 | Method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL387051A PL231885B1 (pl) | 2009-01-16 | 2009-01-16 | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL387051A1 true PL387051A1 (pl) | 2010-07-19 |
| PL231885B1 PL231885B1 (pl) | 2019-04-30 |
Family
ID=42062686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL387051A PL231885B1 (pl) | 2009-01-16 | 2009-01-16 | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8536171B2 (pl) |
| EP (2) | EP2389364B1 (pl) |
| PL (1) | PL231885B1 (pl) |
| WO (1) | WO2010082858A2 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2542535E (pt) | 2010-03-01 | 2014-08-25 | Metriopharm Ag | Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas |
| RU2532128C1 (ru) * | 2013-05-22 | 2014-10-27 | Закрытое акционерное общество "Управляющая компания "Световит" | Способ получения о-люминолятов щелочных металлов |
| RU2577849C2 (ru) * | 2013-09-25 | 2016-03-20 | Общество с ограниченной ответственностью "Сэлвим" | Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита |
| WO2016096143A1 (de) * | 2014-12-18 | 2016-06-23 | Metriopharm Ag | Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| WO2017117586A1 (en) * | 2015-12-31 | 2017-07-06 | Bach Pharma, Inc. | Compositions and nethods for treating brain dysfunction |
| CA3011766C (en) * | 2016-02-16 | 2023-08-01 | Metriopharm Ag | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
| EP3248602A1 (en) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae |
| RU2625267C1 (ru) * | 2016-09-22 | 2017-07-12 | Общество с ограниченной ответственностью "АБИДАФАРМА" | Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты |
| WO2018082814A1 (en) | 2016-11-07 | 2018-05-11 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis |
| EP3511325A1 (en) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
| US20210379063A1 (en) | 2018-10-26 | 2021-12-09 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis |
| EP3858358A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
| EP3858328A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| CN115768402A (zh) | 2020-03-25 | 2023-03-07 | 麦翠奥制药公司 | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 |
| RU2744858C1 (ru) * | 2020-04-28 | 2021-03-16 | Межрегиональное общественное учреждение "Институт инженерной физики" | Способ получения лиофилизата аминодигидрофталазиндион натрия - лекарственного препарата "Тамерон" |
| EP4164651B1 (en) | 2020-06-10 | 2025-10-15 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections |
| EP3981405A1 (en) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
| PH12022553236A1 (en) | 2020-07-09 | 2024-02-12 | Metriopharm Ag | Glucocorticoid-sparing agent |
| US20240075029A1 (en) | 2020-12-02 | 2024-03-07 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
| RU2756568C1 (ru) * | 2021-03-24 | 2021-10-01 | Акционерное общество "Щелково Агрохим" | Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме |
| EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
| EP4209219A1 (en) | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| EP4248963A1 (en) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester |
| EP4483879A1 (en) | 2023-06-29 | 2025-01-01 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders |
| WO2025067689A1 (en) | 2023-09-26 | 2025-04-03 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus |
| PL448122A1 (pl) * | 2024-03-27 | 2025-09-29 | Uniwersytet Jagielloński | Sposób syntezy luminolu |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH683966A5 (it) | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa. |
| RU2113222C1 (ru) | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
| RU2138264C1 (ru) | 1999-05-06 | 1999-09-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата галавит |
| EP1203587B1 (en) * | 2000-03-28 | 2010-07-14 | Abidov, Musea Tazhudinovich | A medicament and method for the production thereof |
| RU2169139C1 (ru) | 2000-08-02 | 2001-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона |
| RU2223227C2 (ru) | 2001-08-10 | 2004-02-10 | Уральский электрохимический комбинат | Установка для испарения гексафторида урана |
| RU2222327C2 (ru) | 2002-03-22 | 2004-01-27 | Общество с ограниченной ответственностью "Абидофарма" | Способ получения лекарственного препарата |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| RU2233161C1 (ru) | 2003-04-18 | 2004-07-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
| US8592421B2 (en) * | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| RU2312663C1 (ru) * | 2006-02-21 | 2007-12-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ лечения острого деструктивного панкреатита |
| RU2320345C1 (ru) * | 2006-07-19 | 2008-03-27 | ГУ Научно-исследовательский институт психического здоровья Томского научного центра Сибирского отделения Российской академии медицинских наук | Способ лечения больных герпетиформной экземой капоши при формировании конверсионного расстройства |
| WO2010036711A1 (en) | 2008-09-23 | 2010-04-01 | Bach Pharma Inc. | Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors |
-
2009
- 2009-01-16 PL PL387051A patent/PL231885B1/pl unknown
-
2010
- 2010-01-15 US US13/144,838 patent/US8536171B2/en active Active
- 2010-01-15 EP EP10705930.5A patent/EP2389364B1/en active Active
- 2010-01-15 WO PCT/PL2010/000005 patent/WO2010082858A2/en not_active Ceased
- 2010-01-15 EP EP16165549.3A patent/EP3072888A1/en not_active Withdrawn
-
2013
- 2013-09-16 US US14/027,901 patent/US9101629B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8536171B2 (en) | 2013-09-17 |
| US20140113902A1 (en) | 2014-04-24 |
| PL231885B1 (pl) | 2019-04-30 |
| EP2389364A2 (en) | 2011-11-30 |
| EP2389364B1 (en) | 2016-10-26 |
| WO2010082858A3 (en) | 2010-11-04 |
| WO2010082858A2 (en) | 2010-07-22 |
| US20110275642A1 (en) | 2011-11-10 |
| EP3072888A1 (en) | 2016-09-28 |
| US9101629B2 (en) | 2015-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL387051A1 (pl) | Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynie | |
| GB2470483B (en) | Improvements in the management of medical tubing | |
| GB2474364B (en) | Hairbrush, methods of use, and methods of manufacturing the same | |
| ZA201200882B (en) | Medical supplies and method of producing the same | |
| PL2536778T3 (pl) | Sposób wytwarzania węglanopolioli polieterowych za pomocą katalizatorów typu podwójnego cyjanku metalu i w obecności soli metali | |
| HRP20130392T1 (hr) | Kateter koji sadrži kompozitnu vodilicu i postupci za uporabu i njegovu proizvodnju | |
| AP2011005943A0 (en) | Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use. | |
| GB0921528D0 (en) | Carbon and its use in blood cleansing applications | |
| SI2279276T1 (sl) | Nerjavni jekleni proizvod, uporaba proizvoda in postopek njegove izdelave | |
| EP2367866A4 (en) | POLYESTER, MANUFACTURING METHOD THEREFOR AND USE | |
| ZA201104896B (en) | Defining simple and complex animations | |
| GB201108964D0 (en) | Medicament and method of diagnosis | |
| PL2393948T3 (pl) | Sposób wytwarzania stopów metali alkalicznych i metali ziem alkalicznych oraz zastosowanie stopów metali alkalicznych i metali ziem alkalicznych | |
| IL212672A (en) | Cycloandesdepsipeptide compounds and their use in drug production | |
| GB0920258D0 (en) | New medical agents and use thereof | |
| ZA201206740B (en) | Aildenafil citrate crystal form o,preparation method and use thereof | |
| IL215980A (en) | An intermediate substance of Artemnam, a preparation containing it and methods for its preparation | |
| PL2501380T3 (pl) | Powolny wlew sulkardyny i jej soli | |
| GB2488494B (en) | Solution, use and method of preparation thereof | |
| ZA201203286B (en) | Therapeutic and diagnostic applications against trypanosomosis | |
| ZA201106884B (en) | Process for the preparation of doxazosin and salts thereof | |
| GB201013829D0 (en) | Human in vitro model of the blood cerebrospinal fluid barrier | |
| PL2491021T3 (pl) | Nowe acylopiperazynony i ich zastosowanie jako środki farmaceutyczne | |
| EP2350212A4 (en) | POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF | |
| GB0909380D0 (en) | Method and use |